Alaunos Therapeutics, Inc. TCRT
We take great care to ensure that the data presented and summarized in this overview for Alaunos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TCRT
View all-
Gamble Jones Investment Counsel61KShares$145,1800.0% of portfolio
-
Altium Wealth Management LLC15KShares$35,7000.0% of portfolio
-
Sawtooth Solutions, LLC14.3KShares$33,9150.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.1KShares$4,9980.0% of portfolio
-
Trustcore Financial Services, LLC250Shares$5950.0% of portfolio
Latest Institutional Activity in TCRT
Top Purchases
Top Sells
About TCRT
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Insider Transactions at TCRT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2023
|
Kevin S. Boyle Sr. Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
68,014
-7.85%
|
$0
$0.14 P/Share
|
|
Nov 29
2022
|
Jaime Vieser |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+50.0%
|
$0
$0.65 P/Share
|
|
Nov 29
2022
|
Robert W Postma |
BUY
Open market or private purchase
|
Indirect |
750,000
+13.04%
|
$0
$0.65 P/Share
|
|
Aug 30
2022
|
Kevin S. Boyle Sr. Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,750
-2.12%
|
$37,500
$2.41 P/Share
|
|
Jun 22
2022
|
Holger Weis |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.98%
|
-
|
|
Jun 22
2022
|
Christopher Bowden Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+47.52%
|
-
|
|
Jun 22
2022
|
Jaime Vieser |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+5.09%
|
-
|
|
Jun 22
2022
|
Robert W Postma |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+3.12%
|
-
|
|
Jun 22
2022
|
James Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+29.81%
|
-
|
|
Jun 22
2022
|
Mary Thistle Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+47.06%
|
-
|
|
Dec 22
2021
|
Eleanor De Groot EVP, Operations |
SELL
Open market or private sale
|
Direct |
20,132
-7.83%
|
$20,132
$1.27 P/Share
|
|
Nov 17
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,116
+1.02%
|
$9,116
$1.4 P/Share
|
|
Nov 16
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
884
+0.1%
|
$884
$1.4 P/Share
|
|
Sep 29
2021
|
Jaime Vieser |
BUY
Open market or private purchase
|
Direct |
100,000
+12.42%
|
$100,000
$1.91 P/Share
|
|
Sep 02
2021
|
Robert W Postma |
BUY
Open market or private purchase
|
Indirect |
54,492
+1.27%
|
$54,492
$1.73 P/Share
|
|
Sep 02
2021
|
Robert W Postma |
BUY
Open market or private purchase
|
Direct |
20,508
+1.68%
|
$20,508
$1.73 P/Share
|
|
Sep 02
2021
|
Heidi Hagen Director |
BUY
Open market or private purchase
|
Direct |
23,770
+14.01%
|
$23,770
$1.76 P/Share
|
|
Sep 01
2021
|
James Huang Director |
BUY
Open market or private purchase
|
Direct |
100,000
+48.0%
|
$100,000
$1.71 P/Share
|
|
Sep 01
2021
|
Holger Weis |
BUY
Open market or private purchase
|
Direct |
50,000
+29.38%
|
$50,000
$1.83 P/Share
|
|
Aug 30
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
875,000
+50.0%
|
-
|